News／Press Release

Apr.07, 2025
TAK-Circulator and Prof. Nathan Bartlett (The University of Newcastle, Australia) initiated a study investigating the TAKC-02 inhibition of Rhinovirus-Induced Inflammation in Primary Human Bronchial Epithelial Cells.(Open Link)​

​Sep.17, 2024
Will exhibit at “JAPAN HEALTHCARE VENTURE SUMMIT 2024” on 9-11 October 2024.(Open Link) 

May.02, 2024
TAKC-02 Exploratory Clinical Study Completion has been registered (jRCTs031220218)

​Feb.21, 2024
Our company's article is published on Nikkei Biotech ONLINE (2024.2.21)
"TAK-Circulator is developing Gapmer-type antisense nucleic acid for asthma (Open link )"
Membership registration is required to view the full text.

​Sep.06, 2022
Exhibited at “JAPAN HEALTHCARE VENTURE SUMMIT 2022” on 12-14 October 2022.(Open Link) 
July.20, 2022
TAKC-02 Exploratory Clinical Study registered (jRCTs031220218). 
(The exploratory clinical study of the oligonucleotide drug for male patients with moderate asthma)
​Jan.11, 2022
Selected for the “Jury's Special Award” at the Japan Healthcare Venture Summit 2021 (JHVS2021), which is given to those who have a particularly high possibility of practical application and potential of seeds.
The exhibitor pitch was held by the Ministry of Health, Labor and Welfare on 13-15 October 2021.(Open Link. Japanese release only)
May.19, 2022
Completed the Phase I Clinical Study of TAKC-02 (NCT05018533)
Aug.17, 2021
Started enrollment of TAKC-02 Phase I Clinical Study (NCT05018533). ​
Aug.10, 2021
​Exhibited at “JAPAN HEALTHCARE VENTURE SUMMIT 2021” on 13-15 October 2021.
​Mar.29,2021
Nippon Shokubai Co., Ltd. has released a press release regarding the Completion of GMP Manufacturing for Oligonucleotide API. (Open Link)​
Sep.10, 2019
​TAK-Circulator Announces to Collaborate on Development of TAKC-02 and Expand a Capital Alliance with Nippon Shokubai Co .,ltd through Third Party Allotment（Open Link）
Aug.02, 2016
​TAK-Circulator Announces to Form a Capital Alliance with Nippon Shokubai Co.,ltd. （Open Link）